Smart Cancer Guide

Introduction Pancreatic cancer is one of the most aggressive cancers, with complex nutritional and treatment needs. While  surgery, chemotherapy, and targeted therapies remain the standard of care , research increasingly explores  supplemental, metabolic, and repurposed-drug strategies  to support digestion, reduce inflammation, and modulate tumor metabolism. This guide combines  evidence-based supplements, selenium research, metabolic therapy approaches, and the Bigelsen protocol  for an up-to-date, integrative perspective. 1. Pancreatic Enzyme Replacement Therapy (PERT) Pancreatic exocrine insufficiency (PEI) is common in pancreatic cancer, leading to poor digestion, malnutrition, and weight loss. Key Points: PERT helps digest fats, proteins, and carbohydrates . Crucial after surgeries like the Whipple procedure . Prescription options (Creon, Pancreaze) are recommended; over-the-counter enzymes vary in potency. Dosing should be guided by a healthcare professio...

Looking for a Cancer Specialist in USA?  Information is a powerful tool when you or a loved one is facing a critical healthcare decision—especially when selecting a hospital or care team for cancer treatment. This choice can directly impact lives, making it essential to choose wisely. One of the things cancer patients often experience is that everyone around them seems to have advice—drink this, take that, see this therapist, stop eating certain foods, start eating others. It can quickly become overwhelming. For patients, it’s a new and unfamiliar situation, and they often lack the experience to navigate it effectively. The real danger is that patients may try to do too much, picking bits and pieces from different recommendations. A sense of panic can creep in, fueled by the fear of missing out on something that could help. This vulnerability also leaves them at greater risk of falling for unproven or even harmful "miracle cures" promoted by unscrupulous individuals. This is ...

Artificial Intelligence (AI) is rapidly transforming oncology —from early detection and diagnosis to drug discovery, treatment selection, and clinical research. Many cancer experts believe AI will reshape cancer care over the next decade in a similar way that genomics did in the early 2000s. Below are the most important ways AI is changing cancer treatment and oncology research . 1. Earlier Cancer Detection One of the biggest benefits of AI is detecting cancer earlier than traditional methods . AI models can analyze: medical imaging pathology slides blood biomarkers genetic data AI in imaging AI systems can detect subtle patterns in medical scans that radiologists might miss. In some cases, imaging data may be noisy or difficult to interpret due to resolution limits, motion artifacts, or incomplete scan coverage. AI algorithms can analyze these images in real time, identifying anomalies, missing anatomical regions, or areas that require closer review. When potential issues are detected...

Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies. The high cost of oncology drugs-exceeding $150 billion globally in 2022-and the slow pace of new drug approvals further complicate timely patient access to effective therapies. In this context, drug repurposing-the strategy of identifying new therapeutic uses for existing drugs-has emerged as a promising approach to accelerate cancer treatment development while reducing costs and safety risks. Among repurposed candidates , antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin have attracted considerable attention due to their ...

Colorectal cancer — once considered a disease of older adults — is now the number one cause of cancer-related death in Americans under age 50 , according to new research published in the Journal of the American Medical Association (JAMA). This alarming shift marks a major public-health milestone and highlights the urgent need for better awareness, early screening, and research into causes.  A Dramatic Shift in Cancer Mortality Trends Until recently, cancers like lung, breast, and leukemia were the top killers for people under 50. But a new analysis of U.S. cancer mortality data from 1990 through 2023 shows that colorectal cancer (CRC) mortality has increased by about 1.1% per year , even as deaths from most major cancers have declined. By 2023, colorectal cancer had risen from the fifth leading cause of cancer death in younger adults to the first . ( American Hospital Association ) Key Trend Drivers Decreases in death rates for other cancers (lung, breast, leukemia, brain). ...

Abstract Prostate cancer remains one of the most prevalent malignancies among men worldwide, with substantial heterogeneity in risk, progression, and therapeutic response. While advances in androgen receptor–targeted therapies and immunotherapy have improved outcomes in metastatic disease, overall survival gains remain modest for many patients. Concurrently, growing evidence suggests that lifestyle factors, dietary patterns, environmental exposures, and socioeconomic determinants play a critical role in disease risk and post-diagnosis survival. This review synthesizes recent evidence on prostate cancer risk factors and prevention, evaluates contemporary treatment strategies and guideline updates through 2025–2026, summarizes the evolving clinical trial landscape, and critically examines emerging case series involving repurposed antiparasitic agents such as fenbendazole and ivermectin. The convergence of population-level prevention, precision oncology, and real-world patient experimenta...

An Evidence-Based Framework for Patients, Caregivers, Clinicians, Investors, and Health Writers Cancer studies are often misunderstood because headlines emphasize dramatic results without context. To avoid being misled, first identify the study type: preclinical research (lab or animal studies) cannot prove effectiveness in humans, while randomized controlled trials (RCTs) provide stronger evidence. Next, check the trial phase—Phase I tests safety, Phase II explores activity, and Phase III determines whether treatment should change clinical practice. Always compare relative risk with absolute risk reduction . A “50% reduction” may translate into only a small real-world benefit. Look at meaningful outcomes like overall survival and quality of life rather than surrogate endpoints such as progression-free survival. Review sample size, hazard ratios, confidence intervals, and funding sources. Finally, ask whether respected organizations like the National Comprehensive Cancer Network or ...

Abstract Background:  Stage IV pancreatic ductal adenocarcinoma (PDAC) lacking actionable mutations has limited treatment options, with median overall survival (mOS) of 9–11 months using standard chemotherapy. Repurposed drugs (ivermectin, mebendazole) and hyperthermia show preclinical promise. This in silico randomized controlled trial (RCT) evaluates an integrative protocol combining ivermectin, mebendazole, hyperthermia, supplements, and lifestyle interventions versus standard-of-care (SOC) NALIRIFOX chemotherapy in non-BRCA-mutated stage IV PDAC. Methods:  A simulated two-arm RCT enrolled 200 patients with non-BRCA-mutated stage IV PDAC, randomized 1:1 to an experimental arm (ivermectin 1 mg/kg/day 3 days/week, mebendazole 500 mg twice daily, localized hyperthermia 42–43°C 3 sessions/week, supplements [vitamin C, vitamin D, curcumin, berberine], ketogenic diet, intermittent fasting, pancreatic enzymes) or control arm (NALIRIFOX). Primary endpoint was 12-month overall surv...